Follow the Innovent Biologics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in Hong Kong. Shares are quoted on the HK market, under the supervision of HKEX. Operating in the Health Care sector, Innovent Biologics, Inc. has published 19 reports. Market capitalisation: €177.5bn. The latest transaction was reported on 7 September 2026 (Purchase). Among the most active insiders: Ede Ronald Hao Xi. The full history is openly available.
19
Insider Decl.
n/a
Thresholds
n/a
9 ops.
Buy Volume
€59m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Innovent Biologics, Inc. Strong Buy (bullish), based on 28 analysts. Average price target: HK$128.58.
31Σ signal
Buys n/a€59m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,438 of 29,063 companies
56.9
score / 100
Value
51
Quality
63
FCF yld5.2%
Earn yld0.5%
EV/EBITDA·
ROE7.0%
Gross mgn87%
Net mgn6.2%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Innovent Biologics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de fármacos innovadores para el tratamiento del cáncer y otras enfermedades. Cotiza en la Bolsa de Hong Kong bajo el símbolo XHKG.